驱动基因阴性晚期非小细胞肺癌免疫检查点抑制剂一线单药及联合化疗治疗进展
Progress of Immune Checkpoint Inhibitors as First-Line Monotherapy and Combined Chemotherapy for Advanced Non-Small Cell Lung Cancer with Negative Driver Genes
DOI: 10.12677/ACM.2023.1381815, PDF,   
作者: 张学文, 陈 杰, 郑凯曼：青海大学研究生院，青海 西宁；姜 军*：青海大学附属医院肿瘤内科，青海 西宁
关键词: 驱动基因阴性；非小细胞肺癌；免疫检查点抑制剂；化疗；Driver Genes Were Negative； Non-Small Cell Lung Cancer； Immune Checkpoint Inhibitors； Chemotherapy
摘要: 我国是肺癌的第一大国，发病率和死亡率居所有恶性肿瘤之首。非小细胞肺癌在肺癌中最为常见，约占所有肺癌的80~85%。EGFR突变阴性及ALK重排阴性等驱动基因阴性的晚期或转移性非小细胞肺癌(NSCLC)的治疗仍面临挑战，随着免疫治疗时代帷幕的拉开，免疫检查点抑制剂进入我们的视线，现有许多围绕其开展的大型III期临床试验汇报了它在此类患者中的疗效，且大部分研究都在一定程度上改善了患者预后，同时也为患者带来了不同于传统治疗模式的治疗相关不良反应。本文聚焦于驱动基因阴性的晚期非小细胞肺癌免疫检查点抑制剂一线治疗的疗效及安全性，以期为后续临床免疫治疗策略提供思路和线索。
Abstract: Lung cancer is the most common disease in China, and its morbidity and mortality rank the first among all malignant tumors. Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for about 80%~85% of all lung cancers. The treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with negative driver genes such as EGFR mutation and ALK re-arrangement is still facing challenges. With the opening of the immunotherapy era, immune checkpoint inhibitors have come into our attention. Many large Phase III clinical trials have been conducted to report its efficacy in such patients, and most of the studies have improved patient outcomes to some extent, while also bringing about treatment-related adverse effects in patients that are different from traditional treatment modalities. This review focuses on the efficacy and safety of immune checkpoint inhibitors in the first-line treatment of advanced NSCLC with negative driver genes, in order to provide ideas and clues for the subsequent optimization of clinical immu-notherapy strategies.
文章引用：张学文, 陈杰, 郑凯曼, 姜军. 驱动基因阴性晚期非小细胞肺癌免疫检查点抑制剂一线单药及联合化疗治疗进展[J]. 临床医学进展, 2023, 13(8): 12959-12970. https://doi.org/10.12677/ACM.2023.1381815

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
[3] 元玫雯, 王宏昊, 段如菲, 徐坤鹏, 胡尚英, 乔友林, 张勇, 赵方辉. 2016年中国归因于人乳头瘤病毒感染的肿瘤发病与死亡分析[J]. 中华流行病学杂志, 2022, 43(5): 702-708.
[4] Ingrand, I., Defossez, G., Lafay-Chebassier, C., Chavant, F., Ferru, A., Ingrand, P. and Pérault-Pochat, M.C. (2020) Serious Adverse Effects Occurring after Chemotherapy: A General Cancer Registry-Based Incidence Sur-vey. British Journal of Clinical Pharmacology, 86, 711-722. [Google Scholar] [CrossRef] [PubMed]
[5] Planchard, D., Popat, S., Kerr, K., Van Schil, P.E., Hellmann, M.D., Peters, S., et al. (2019) Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 30, 863-870. [Google Scholar] [CrossRef] [PubMed]
[6] Abdel, K.N. and Kelly, K. (2019) Role of Targeted Therapy and Im-mune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. The Oncologist, 24, 1270-1284. [Google Scholar] [CrossRef] [PubMed]
[7] Camidge, D.R., Pao, W. and Sequist, L.V. (2014) Acquired Resistance to TKIs in Solid Tumours: Learning from Lung Cancer. Nature Reviews Clinical Oncology, 11, 473-481. [Google Scholar] [CrossRef] [PubMed]
[8] Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135. [Google Scholar] [CrossRef] 
[9] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 1627-1639. [Google Scholar] [CrossRef] 
[10] Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenk-iste, J., Mazieres, J., et al. (2016) Atezolizumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial. The Lancet, 387, 1837-1846. [Google Scholar] [CrossRef] 
[11] Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Pérez-Gracia, J.L., Han, J.Y., et al. (2015) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomized Controlled Trial. The Lancet, 387, 1540-1550. [Google Scholar] [CrossRef] 
[12] Sundar, R., Cho, B.C., Brahmer, J.R. and Soo, R.A. (2015) Nivolumab in NSCLC: Latest Evidence and Clinical Potential. Therapeutic Advances in Medical Oncology, 7, 85-96. [Google Scholar] [CrossRef] [PubMed]
[13] Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. and Honjo, T. (2001) PD-1 Immunoreceptor Inhibits B Cell Receptor-Mediated Signaling by Recruiting Src Homology 2-Domain-Containing Tyrosine Phosphatase 2 to Phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America, 98, 13866-13871. [Google Scholar] [CrossRef] [PubMed]
[14] Chauhan, D.S., Mudaliar, P., Basu, S., Aich, J. and Paul, M.K. (2022) Tumor-Derived Exosome and Immune Modulation. In: Paul, M.K., Eds., Extracellular Vesicles, IntechOpen. [Google Scholar] [CrossRef] 
[15] Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. [Google Scholar] [CrossRef] [PubMed]
[16] Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., et al. (2022) Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Frontiers in Immunology, 12, Article 799455. [Google Scholar] [CrossRef] [PubMed]
[17] Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. [Google Scholar] [CrossRef] 
[18] Lahiri, A., Maji, A., Potdar, P.D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A. and Paul, M.K. (2023) Lung Cancer Immunotherapy: Progress, Pitfalls, and Promises. Molecu-lar Cancer, 22, Article No. 40. [Google Scholar] [CrossRef] [PubMed]
[19] 高磊, 俞阳, 李晓梅, 刘乾, 尹振宇, 陈昊. 化疗与免疫检查点抑制剂联用对肿瘤治疗的作用[J/OL]. 解放军医学杂志: 1-11[2022-07-25].
https://kns.cnki.net/kcms2/article/abstract?v=KTWJcyGkBkCExXube66KZJbWU0ZvgXrwIMSz0aPwu94OKXxfieUWvVq1eInQpSk7uX2WXoDM7OLUBz2rTGplyA5seopv-fouuYvHD7gTa4JuXQVr6d4xfFDfUhF-cy8ScKryRlsHl60=&uniplatform=NZKPT&language=CHS
[20] Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028. [Google Scholar] [CrossRef] 
[21] Garon, E.B., Hellmann, M.D., Rizvi, N.A., Carcereny, E., Leighl, N.B., Ahn, M.J., Eder, J.P., Balmanoukian, A.S., Aggarwal, C., Horn, L., Patnaik, A., Gubens, M., Ramalingam, S.S., Felip, E., Goldman, J.W., Scalzo, C., Jensen, E., Kush, D.A. and Hui, R. (2019) Five-Year Overall Survival for Patients with Advanced Non-Small-Cell Lung Cancer Treated with Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Journal of Clinical Oncology, 37, 2518-2527. [Google Scholar] [CrossRef] 
[22] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833. [Google Scholar] [CrossRef] 
[23] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leal, T.A., Riess, J.W., Jensen, E., Zhao, B., Pietanza, M.C. and Brahmer, J.R. (2021) Five-Year Outcomes with Pembrolizumab versus Chem-otherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, 39, 2339-2349. [Google Scholar] [CrossRef] 
[24] Mok, T.S.K., Wu, Y.L., Kudaba, I., Kowalski, D.M., Cho, B.C., Turna, H.Z., Castro Jr, G., Srimuninnimit, V., Laktionov, K.K., Bondarenko, I., Kubota, K., Lubiniecki, G.M., Zhang, J., Kush, D., Lopes, G. and KEYNOTE-042 Investigators. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830.
[25] Gettinger, S., Rizvi, N.A., Chow, L.Q., Bor-ghaei, H., Brahmer, J., Ready, N., et al. (2016) Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 34, 2980-2987. [Google Scholar] [CrossRef] 
[26] Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M.M., Ciuleanu, T.E., Badin, F., Ready, N., Hiltermann, T.J.N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J.M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein Jr, G.R., Villaruz, L.C., Havel, L., Krejci, J., Corral Jaime, J., Chang, H., Geese, W.J., Bhagavatheeswaran, P., Chen, A.C., Socinski, M.A. and CheckMate 026 Investigators (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 376, 2415-2426. [Google Scholar] [CrossRef] 
[27] Peters, S., Gettinger, S., Johnson, M.L., Jänne, P.A., Garassino, M.C., Christoph, D., et al. (2017) Phase II Trial of Atezolizumab as First-Line Orsubsequent Therapy for Patients with Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 35, 2781-2789. [Google Scholar] [CrossRef] 
[28] Herbst, R.S., Giaccone, G., de Marinis, F., et al. (2020) Atezoli-zumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. The New England Journal of Medicine, 383, 1328-1339. [Google Scholar] [CrossRef] 
[29] Verschraegen, C.F., Jerusalem, G., McClay, E.F., Ian-notti, N., Redfern, C.H., Bennouna, J., Chen, F.L., Kelly, K., Mehnert, J., Morris, J.C., Taylor, M., Spigel, D., Wang, D., Grote, H.J., Zhou, D., Munshi, N., Bajars, M. and Gulley, J.L. (2020) Efficacy and Safety of First-Line Avelumab in Pa-tients with Advanced Non-Small Cell Lung Cancer: Results from a Phase Ib Cohort of the JAVELIN Solid Tumor Study. Journal for ImmunoTherapy of Cancer, 8, e001064. [Google Scholar] [CrossRef] [PubMed]
[30] Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H.M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Gao, B., Li, S., Lee, S., McGuire, K., Chen, C.I., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D.M., Yancopou-los, G.D., Gullo, G., Lowy, I. and Rietschel, P. (2021) Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with PD-L1 of at Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial. The Lancet, 397, 592-604. [Google Scholar] [CrossRef] 
[31] Rapoport, B.L. and Anderson, R. (2019) Realizing the Clini-cal Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy. International Journal of Molecular Sciences, 20, Article 959. [Google Scholar] [CrossRef] [PubMed]
[32] 于颖彦. 免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(1): 48-52. [Google Scholar] [CrossRef] 
[33] Langer, C.J., Gadgeel, S.M., Borghaei, H., Papadimi-trakopoulou, V.A., Patnaik, A., Powell, S.F., et al. (2016) Carboplatin and Pemetrexed with or without Pembrolizumab for Advanced, Non-Squamous Non-Small-Cell Lung Cancer: A Randomised, Phase 2 Cohort of the Open-Label KEYNOTE-021 Study. The Lancet Oncology, 17, 1497-1508. [Google Scholar] [CrossRef] 
[34] Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E. and Felip, E. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092. [Google Scholar] [CrossRef] 
[35] Horinouchi, H., Nogami, N., Saka, H., Nishio, M., Tokito, T., Takahashi, T., Kasahara, K., Hattori, Y., Ichihara, E., Adachi, N., Noguchi, K., Souza, F. and Kurata, T. (2021) Pem-brolizumab plus Pemetrexed-Platinum for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: KEYNOTE-189 Ja-pan Study. Cancer Science, 112, 3255-3265. [Google Scholar] [CrossRef] [PubMed]
[36] Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Deng, X., Zhang, Y., Bas, T., Piperdi, B. and Halmos, B. (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab plus Chemotherapy in Patients with Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 15, 1657-1669. [Google Scholar] [CrossRef] [PubMed]
[37] Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodríguez-Abreu, D., Hussein, M., Soo, R., Conter, H.J., Kozuki, T., Huang, K.C., Graupner, V., Sun, S.W., Hoang, T., Jes-sop, H., McCleland, M., Ballinger, M., Sandler, A. and Socinski, M.A. (2020) Atezolizumab in Combination with Car-boplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results from a Randomized Phase III Trial. Journal of Thoracic Oncology, 15, 1351-1360. [Google Scholar] [CrossRef] [PubMed]
[38] West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H.J.., Kopp, H.G., Daniel, D., McCune, S., Mekhail, T., Zer, A., Reinmuth, N., Sadiq, A., Sandler, A., Lin, W., Ochi Lohmann, T., Archer, V., Wang, L., Kowanetz, M. and Cappuzzo, F. (2019) Atezolizumab in Combination with Carboplatin plus Nab-Paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-Line Treatment for Meta-static Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 924-937. [Google Scholar] [CrossRef] 
[39] Nishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Co-bo, M., Longeras, P.D., Goldschmidt Jr, J., Novello, S., Orlandi, F., Sanborn, R.E., Szalai, Z., Ursol, G., Mendus, D., Wang, L., Wen, X., McCleland, M., Hoang, T., Phan, S. and Socinski, M.A. (2021) Atezolizumab plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. Journal of Thoracic Oncology, 16, 653-664. [Google Scholar] [CrossRef] [PubMed]
[40] Zhang, L., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Stefaniak, V., Lin, Y., Wang, S., Zhang, W., Sun, L. and Yang, Y. (2022) Final Overall Survival Data of Sintilimab plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. Lung Cancer, 171, 56-60. [Google Scholar] [CrossRef] [PubMed]
[41] Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., Zhou, J., Zhou, C., Li, B., Li, J., Fan, M., Cui, J., Li, Y., Zhao, H., Fang, J., Xue, J., Hu, C., Sun, P., Du, Y., Zhou, H., Wang, S. and Zhang, W. (2021) Sintilimab plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results from a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). Journal of Thoracic Oncology, 16, 1501-1511. [Google Scholar] [CrossRef] [PubMed]
[42] Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., Wang, Q., Cheng, Y., Wu, F., Chen, J., Lin, X., Wang, Y., Huang, J., Cui, J., Cao, L., Liu, Y., Zhang, Y., Pan, Y., Zhao, J., Wang, L., Chang, J., Chen, Q., Ren, X., Zhang, W., Fan, Y., He, Z., Fang, J., Gu, K., Dong, X., Jin, F., Gao, H., An, G., Ding, C., Jiang, X., Xiong, J., Zhou, X., Hu, S., Lu, P., Liu, A., Guo, S., Huang, J., Zhu, C., Zhao, J., Gao, B., Chen, Y., Hu, C., Zhang, J., Zhang, H., Zhao, H., Tai, Y., Ma, X., Shi, W. and CameL Study Group (2023) Camrelizumab plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial. Journal of Thoracic Oncology, 18, 628-639. [Google Scholar] [CrossRef] [PubMed]
[43] Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., Yao, W., Wang, R., Li, X., Zhang, W., Zhang, Y., Hu, S., Guo, R., Shi, J., Wang, Z., Cao, P., Wang, D., Fang, J., Luo, H., Geng, Y., Xing, C., Lv, D., Zhang, Y., Yu, J., Cang, S., Yang, Z., Shi, W., Zou, J., Zhou, C. and CameL-sq Study Group (2022) Camrelizumab plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of Thoracic Oncology, 17, 544-557. [Google Scholar] [CrossRef] [PubMed]
[44] Lu, S., Wang, J., Yu, Y., Yu, X., Hu, Y., Ai, X., Ma, Z., Li, X., Zhuang, W., Liu, Y., Li, W., Cui, J., Wang, D., Liao, W., Zhou, J., Wang, Z., Sun, Y., Qiu, X., Gao, J., Bao, Y., Liang, L. and Wang, M. (2021) Tislelizumab plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 16, 1512-1522. [Google Scholar] [CrossRef] [PubMed]
[45] Wang, J., Lu, S., Yu, X., Hu, Y., Sun, Y., Wang, Z., Zhao, J., Yu, Y., Hu, C., Yang, K., Feng, G., Ying, K., Zhuang, W., Zhou, J., Wu, J., Leaw, S.J., Zhang, J., Lin, X., Liang, L. and Yang, N. (2021) Tislelizumab plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Ad-vanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 7, 709-717. [Google Scholar] [CrossRef] [PubMed]
[46] Paz-Ares, L.G., Ramalingam, S.S., Ciuleanu, T.E., Lee, J.S., Urban, L., Caro, R.B., Park, K., Sakai, H., Ohe, Y., Nishio, M., Audigier-Valette, C., Burgers, J.A., Pluzanski, A., Sangha, R., Gallardo, C., Takeda, M., Linardou, H., Lupinacci, L., Lee, K.H., Caserta, C., Provencio, M., Carcereny, E., Otterson, G.A., Schenker, M., Zurawski, B., Alexandru, A., Vergnenegre, A., Raimbourg, J., Feeney, K., Kim, S.W., Borghaei, H., O’Byrne, K.J., Hellmann, M.D., Memaj, A., Nathan, F.E., Bushong, J., Tran, P., Brahmer, J.R. and Reck, M. (2022) First-Line Nivolumab plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes from the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 17, 289-308. [Google Scholar] [CrossRef] [PubMed]
[47] Paz-Ares, L., Ciuleanu, T.E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Salman, P., Souquet, P.J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., John, T., Carbone, D.P., Mead-ows-Shropshire, S., Agrawal, S., Oukessou, A., Yan, J. and Reck, M. (2021) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An In-ternational, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211. [Google Scholar] [CrossRef] 
[48] Huang, Q., Kemnade, J., Cornwell, L., et al. (2022) Non-Small Cell Lung Cancer in the Era of Immunotherapy. Seminars in Oncology, 49, 337-343. [Google Scholar] [CrossRef] [PubMed]
[49] 李光韬, 张卓莉. 自身免疫性疾病与发热[J]. 中国实用内科杂志, 2016, 36(12): 1032-1035.
[50] Doroshow, D.B., Bhalla, S., Beasley, M.B., Sholl, L.M., Kerr, K.M., Gnjatic, S., Wistuba, I.I., Rimm, D.L., Tsao, M.S. and Hirsch, F.R. (2021) PD-L1 as a Biomarker of Response to Im-mune-Checkpoint Inhibitors. Nature Reviews Clinical Oncology, 18, 345-362. [Google Scholar] [CrossRef] [PubMed]
[51] Shen, X. and Zhao, B. (2018) Efficacy of PD-1 or PD-L1 Inhib-itors and PD-L1 Expression Status in Cancer: Meta-Analysis. The BMJ, 362, k3529. [Google Scholar] [CrossRef] [PubMed]
[52] Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Checkpoint In-hibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249. [Google Scholar] [CrossRef] [PubMed]

为你推荐